Literature DB >> 18430716

Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy.

Michelle Wehling-Henricks1, Sophie Sokolow, Jamie J Lee, Kyu H Myung, S Armando Villalta, James G Tidball.   

Abstract

The immune response to dystrophin-deficient muscle promotes the pathology of Duchenne muscular dystrophy (DMD) and the mdx mouse model of DMD. In this investigation, we find that the release of major basic protein (MBP) by eosinophils is a prominent feature of DMD and mdx dystrophy and that eosinophils lyse muscle cells in vitro by the release of MBP-1. We also show that eosinophil depletions of mdx mice by injections of anti-chemokine receptor-3 reduce muscle cell lysis, although lysis of mdx muscle membranes is not reduced by null mutation of MBP-1 in vivo. However, ablation of MBP-1 expression in mdx mice produces other effects on muscular dystrophy. First, fibrosis of muscle and hearts, a major cause of mortality in DMD, is greatly reduced by null mutation of MBP-1 in mdx mice. Furthermore, either ablation of MBP-1 or eosinophil depletion causes large increases in cytotoxic T-lymphocytes (CTLs) in mdx muscles. The increase in CTLs in MBP-1-null mice does not reflect a general shift toward a Th1 inflammatory response, because the mutation had no significant effect on the expression of interferon-gamma, inducible nitric oxide synthase or tumor necrosis factor. Rather, MBP-1 reduces the activation and proliferation of splenocytes in vitro, indicating that MBP-1 acts in a more specific immunomodulatory role to affect the inflammatory response in muscular dystrophy. Together, these findings show that eosinophil-derived MBP-1 plays a significant role in regulating muscular dystrophy by attenuating the cellular immune response and promoting tissue fibrosis that can eventually contribute to increased mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430716      PMCID: PMC2574717          DOI: 10.1093/hmg/ddn129

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  53 in total

Review 1.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

2.  Lymph node trafficking and antigen presentation by endobronchial eosinophils.

Authors:  H Z Shi; A Humbles; C Gerard; Z Jin; P F Weller
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  T-cell-dependent fibrosis in the mdx dystrophic mouse.

Authors:  J Morrison; Q L Lu; C Pastoret; T Partridge; G Bou-Gharios
Journal:  Lab Invest       Date:  2000-06       Impact factor: 5.662

4.  Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.

Authors:  Stuart Hodgetts; Hannah Radley; Marilyn Davies; Miranda D Grounds
Journal:  Neuromuscul Disord       Date:  2006-08-28       Impact factor: 4.296

5.  Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy.

Authors:  Francesca Andreetta; Pia Bernasconi; Fulvio Baggi; Paolo Ferro; Laura Oliva; Elisa Arnoldi; Ferdinando Cornelio; Renato Mantegazza; Paolo Confalonieri
Journal:  J Neuroimmunol       Date:  2006-04-27       Impact factor: 3.478

6.  Differential extraction of eosinophil granule proteins.

Authors:  Lyo E Ohnuki; Lori A Wagner; Ann Georgelas; David A Loegering; James L Checkel; Douglas A Plager; Gerald J Gleich
Journal:  J Immunol Methods       Date:  2005-10-17       Impact factor: 2.303

7.  Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors.

Authors:  B Cai; M J Spencer; G Nakamura; L Tseng-Ong; J G Tidball
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

8.  Eosinophil major basic protein-1 does not contribute to allergen-induced airway pathologies in mouse models of asthma.

Authors:  K L Denzler; S C Farmer; J R Crosby; M Borchers; G Cieslewicz; K A Larson; S Cormier-Regard; N A Lee; J J Lee
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

9.  Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium.

Authors:  Michelle Wehling-Henricks; Maria C Jordan; Kenneth P Roos; Bo Deng; James G Tidball
Journal:  Hum Mol Genet       Date:  2005-05-25       Impact factor: 6.150

10.  Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation.

Authors:  C G Peterson; V Skoog; P Venge
Journal:  Immunobiology       Date:  1986-03       Impact factor: 3.144

View more
  40 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

2.  Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.

Authors:  Akhilesh Kumar; Shephali Bhatnagar; Ashok Kumar
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

4.  Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.

Authors:  Saurabh Dahiya; Srikanth Givvimani; Shephali Bhatnagar; Natia Qipshidze; Suresh C Tyagi; Ashok Kumar
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

5.  Proinflammatory macrophages enhance the regenerative capacity of human myoblasts by modifying their kinetics of proliferation and differentiation.

Authors:  Maximilien Bencze; Elisa Negroni; Denis Vallese; Houda Yacoub-Youssef; Soraya Chaouch; Annie Wolff; Ahmed Aamiri; James P Di Santo; Bénédicte Chazaud; Gillian Butler-Browne; Wilson Savino; Vincent Mouly; Ingo Riederer
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

Review 6.  The expanding role(s) of eosinophils in health and disease.

Authors:  Elizabeth A Jacobsen; Richard A Helmers; James J Lee; Nancy A Lee
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

7.  Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD).

Authors:  Bruce S Bochner; Wendy Book; William W Busse; Joseph Butterfield; Glenn T Furuta; Gerald J Gleich; Amy D Klion; James J Lee; Kristin M Leiferman; Michael Minnicozzi; Redwan Moqbel; Marc E Rothenberg; Lawrence B Schwartz; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

8.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

Review 9.  Eosinophil granule proteins: form and function.

Authors:  K Ravi Acharya; Steven J Ackerman
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

10.  Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.

Authors:  Michelle Wehling-Henricks; Maria C Jordan; Tomomi Gotoh; Wayne W Grody; Kenneth P Roos; James G Tidball
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.